MarketBeat
15 Sept 2026, 06:02 UTC · 2h ago
Verdict
Headline takes no side. We score VXRT +0.60 across five claims — strongly bullish.
+0.60strongly bullish
More positive than 76% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 4 new · 1 priced in
Vaxart's Phase IIb COVID-19 study has fully enrolled approximately 5,400 participants, with a primary efficacy readout expected in the first half of 2027.
Newpresentation at H.C. Wainwright conference on Sep 15
So whatPositive data in H1 2027 could trigger a $50 million opt-in milestone from Sanofi.
More positive than 91% of claims this week
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
If Sanofi opts into the COVID-19 program following Phase IIb results, Vaxart is eligible for up to $670 million in milestone payments and low- to mid-teens royalties.
Priced inreferences previous license agreement
So whatThe potential payout represents a massive multiple of the company's current micro-cap valuation if triggered in 2027.
More positive than 85% of claims this week
Vaxart's cash runway extends into the first half of 2027, supported by BARDA funding for the COVID-19 study.
Newpresentation at H.C. Wainwright conference on Sep 15
So whatRunway aligns exactly with the H1 2027 COVID readout, minimizing dilution risk until the binary catalyst occurs.
More positive than 66% of claims this week
The company is seeking a partnership or investment to advance its second-generation bivalent norovirus vaccine candidate into a Phase II study.
Newpresentation at H.C. Wainwright conference on Sep 15
So whatLack of existing funding for this $10 billion market opportunity indicates a dependence on external capital to avoid program stalls.
More negative than 66% of claims this week
Vaxart is seeking partnerships or investment to move its influenza programs forward after observing better protection versus Fluzone in a Phase II challenge study.
Newpresentation at H.C. Wainwright conference on Sep 15
More negative than 62% of claims this week
Which stocks this story touches
More positive than 76% of ticker scores this week
The company reported encouraging safety and reactogenicity data in its COVID-19 trial and has a cash runway extending into 2027.
More positive than 48% of ticker scores this week
The company holds a license agreement for Vaxart's COVID-19 program and has the option to opt in based on Phase IIb results.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
MarketBeat
3h ago
—
VXRT hasn't traded since this ran. Last close $0.4900 (Sep 14); the reaction starts at the next open.
VXRT chart →
